As Biotechnology businesses, Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and AC Immune SA (NASDAQ:ACIU), are affected by compare. This especially applies to their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paratek Pharmaceuticals Inc.	5.17M	43.81	111.46M	-3.64	0.00
AC Immune SA	N/A	0.00	N/A	-0.54	0.00

Table 1 highlights Paratek Pharmaceuticals Inc. and AC Immune SA’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

	Net Margins	Return on Equity	Return on Assets
Paratek Pharmaceuticals Inc.	-2,155.90%	-132.5%	-44.6%
AC Immune SA	0.00%	-25.2%	-22.4%

Liquidity

Paratek Pharmaceuticals Inc. has a Current Ratio of 11.4 and a Quick Ratio of 11.4. Competitively, AC Immune SA’s Current Ratio is 19.2 and has 19.2 Quick Ratio. AC Immune SA’s better ability to pay short and long-term obligations than Paratek Pharmaceuticals Inc.

Analyst Recommendations

In next table is shown Paratek Pharmaceuticals Inc. and AC Immune SA’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Paratek Pharmaceuticals Inc.	0	1	1	2.50
AC Immune SA	0	0	0	0.00

Paratek Pharmaceuticals Inc.’s average price target is $13.5, while its potential upside is 92.31%.

Insider & Institutional Ownership

Roughly 82.6% of Paratek Pharmaceuticals Inc. shares are held by institutional investors while 30.3% of AC Immune SA are owned by institutional investors. 2.9% are Paratek Pharmaceuticals Inc.’s share held by insiders. Competitively, insiders own roughly 51.48% of AC Immune SA’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Paratek Pharmaceuticals Inc.	-9.11%	-11.05%	-31.2%	-36.88%	-61.02%	-61.56%
AC Immune SA	-1.53%	24.15%	37.22%	11.28%	-8.75%	-14.45%

For the past year Paratek Pharmaceuticals Inc. was more bearish than AC Immune SA.

Summary

On 7 of the 10 factors AC Immune SA beats Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s (AD), ParkinsonÂ’s, down syndrome, and glaucoma diseases. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies. It also engages in developing ACI-24, a vaccine candidate that is in a combined Phase 1/2a clinical study for AD; and ACI-35, a vaccine candidate against phosphorylated pathological tau and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In addition, the company develops PET ligands that are tracers to target tau and alpha-synuclein aggregates. It has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Biogen International GmbH. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.